NasdaqCM:CFRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has ContraFect's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CFRX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.1%

CFRX

-0.8%

US Biotechs

-0.7%

US Market


1 Year Return

29.5%

CFRX

26.1%

US Biotechs

5.3%

US Market

Return vs Industry: CFRX exceeded the US Biotechs industry which returned 28.5% over the past year.

Return vs Market: CFRX exceeded the US Market which returned 6.7% over the past year.


Shareholder returns

CFRXIndustryMarket
7 Day-4.1%-0.8%-0.7%
30 Day16.3%9.3%4.6%
90 Day-9.2%18.3%14.0%
1 Year29.5%29.5%27.4%26.1%7.6%5.3%
3 Year-54.7%-54.7%30.2%25.8%34.9%26.1%
5 Year-87.4%-87.4%-6.7%-12.0%62.3%44.7%

Price Volatility Vs. Market

How volatile is ContraFect's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ContraFect undervalued compared to its fair value and its price relative to the market?

11.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CFRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CFRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CFRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CFRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CFRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CFRX is overvalued based on its PB Ratio (11.3x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is ContraFect forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

68.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CFRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CFRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CFRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CFRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CFRX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CFRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ContraFect performed over the past 5 years?

12.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CFRX is currently unprofitable.

Growing Profit Margin: CFRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CFRX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.8% per year.

Accelerating Growth: Unable to compare CFRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CFRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: CFRX has a negative Return on Equity (-371.26%), as it is currently unprofitable.


Next Steps

Financial Health

How is ContraFect's financial position?


Financial Position Analysis

Short Term Liabilities: CFRX's short term assets ($22.3M) exceed its short term liabilities ($8.9M).

Long Term Liabilities: CFRX's short term assets ($22.3M) exceed its long term liabilities ($8.9M).


Debt to Equity History and Analysis

Debt Level: CFRX is debt free.

Reducing Debt: CFRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CFRX has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: CFRX is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is ContraFect current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CFRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CFRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CFRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CFRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CFRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Roger Pomerantz (63yo)

1.25yrs

Tenure

US$2,015,033

Compensation

Dr. Roger James Pomerantz, M.D., F.A.C.P., has been Chairman, President and Chief Executive Officer of ContraFect Corporation since April 2, 2019. Dr. Pomerantz serves as Chairman of the Board at Silicon T ...


CEO Compensation Analysis

Compensation vs Market: Roger's total compensation ($USD2.02M) is above average for companies of similar size in the US market ($USD1.35M).

Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Roger Pomerantz
Chairman1.25yrsUS$2.02m0.00029% $511.2
Natalie Bogdanos
General Counsel5.92yrsUS$683.20k0.00029% $511.2
Cara Cassino
Chief Medical Officer and Executive VP of Research & Development4.75yrsUS$932.26k0.0029% $5.1k
Michael Messinger
Chief Financial Officer1.67yrsUS$615.55k0.0069% $12.1k
Nancy Dong
Vice President of Finance & Administration3.33yrsUS$482.25kno data
Michael Wittekind
Consultant3.75yrsUS$794.03kno data

3.5yrs

Average Tenure

56.5yo

Average Age

Experienced Management: CFRX's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Roger Pomerantz
Chairman1.25yrsUS$2.02m0.00029% $511.2
Sol Barer
Lead Independent Director5.17yrsUS$86.50k0.28% $492.4k
Steven Gilman
Vice Chairman1.25yrsUS$551.35k0.0075% $13.2k
Lishan Aklog
Director0.083yrno datano data
Michael Otto
Independent Director6.25yrsUS$73.10k0.0029% $5.1k
Leon Smith
Member of Scientific Advisory Boardno datano datano data
Peter Palese
Member of Scientific Advisory Boardno datano datano data
Adolfo Garcia-Sastre
Member of Scientific Advisory Boardno datano datano data
Vincent Fischetti
Chairman of Scientific Advisory Boardno datano datano data
Cary Sucoff
Independent Director10.17yrsUS$62.48k0.022% $39.3k
David Low
Independent Director6.25yrsUS$74.98k0.13% $234.9k
Daniel Capon
Member of Scientific Advisory Boardno datano datano data

5.2yrs

Average Tenure

67yo

Average Age

Experienced Board: CFRX's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 250.1%.


Top Shareholders

Company Information

ContraFect Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ContraFect Corporation
  • Ticker: CFRX
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$176.277m
  • Shares outstanding: 27.80m
  • Website: https://www.contrafect.com

Number of Employees


Location

  • ContraFect Corporation
  • 28 Wells Avenue
  • 3rd Floor
  • Yonkers
  • New York
  • 10701
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CFRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2014
22R1DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2014

Biography

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/14 00:07
End of Day Share Price2020/07/13 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.